Remove 2015 Remove Leads Remove Pharmacology
article thumbnail

Market outlook to 2032: future trends across the seven major markets

European Pharmaceutical Review

GlobalData’s Analyst covering Neurology and Ophthalmology, Thomas Parker, MPharmacol, predicted that Belsomra would lead the market by 2023. Comparatively, in 2015, GlobalData’s research expected that sales of therapies for Gaucher disease will reach $1.16 million in sales by 2032. billion by 2024.

article thumbnail

Biosimilar medicines: the intersection of access, affordability, and innovation

European Pharmaceutical Review

Over 100 biosimilar medicines are approved for nearly 30 reference medicines, testimony to the rigour of the scientific standards leading to the European authorisation process. These reconsiderations lead the way to liberating untapped potential from biological standards of care. She holds a MSc in Pharmacology. References 1.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Developing new treatment regimens for HIV

European Pharmaceutical Review

In fact, a study published in 2023 in The Lancet HIV revealed that women and men with HIV at age 40 had an average of 39 and 37 years of life left, respectively – only a few years less than that of the general population – if they started antiretroviral therapy (ART) after 2015. World Health Organization. The Global Health Observatory.

article thumbnail

Navigating the unique CMC challenges of oral anaerobic live biotherapeutics

European Pharmaceutical Review

Firstly, the pharmacological response to LBPs does not follow traditional pharmacokinetic principles. LBP drug substance production considerations Lead candidate strains are often isolated from healthy human subjects to establish a master cell bank (MCB). 2015; 69(1):381–403 5. 2021; 19:100306 4.

article thumbnail

Nine for 2023, part two: healthcare’s hard problem, the prognosis for diagnosis, and key new pharmacotherapy platforms

pharmaphorum

Across swathes of primary care, pharmacological innovation has stalled; the last new antihypertensive class was introduced in 2007 and new antibiotics have trickled in at a dangerously slow pace. Alzheimer’s is currently the seventh-leading cause of death globally and growing fast.

FDA 98